Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Linvoseltamab may retain binding to cells w/ BCMA R27P S30del mutations, and demonstrated Jurkat-NFAT reporter and primary T-cell activation, as well as targeted cytotoxicity against mutated BCMA comparable to WT BCMA.”
Title: Distinct Epitope Engagement Confers Differential Activity of Linvoseltamab Versus Teclistamab Across BCMA Mutations
Authors: Yi Zhou, Olga Sineshchekova, Ken Lee, Aneesha Doshi, Kyle Brown, Matthew C. Franklin, Erica Ullman, Aynur Hermann, Glenn S. Kroog, Anita Boyapati, Eric Smith, John C. Lin, William C. Olson, Kara Olson
You can read the Full Article on Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
